

Martina Fabris

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7058809/martina-fabris-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

61
papers

1,591
citations

26
h-index

39
g-index

62
ext. papers

1,980
ext. citations

4.7
avg, IF

4.32
L-index

#	Paper	IF	Citations
61	Post-COVID-19 syndrome and humoral response association after one year in vaccinated and unvaccinated patients.. <i>Clinical Microbiology and Infection</i> , 2022 ,	9.5	1
60	Interleukin 6, soluble interleukin 2 receptor alpha (CD25), monocyte colony-stimulating factor, and hepatocyte growth factor linked with systemic hyperinflammation, innate immunity hyperactivation, and organ damage in COVID-19 pneumonia. <i>Cytokine</i> , 2021 , 140, 155438	4	17
59	Seroconversion and kinetic of anti SARS-COV-2 antibodies in 25 patients with hematological malignancies who recovered from SARS-COV-2 infection. <i>Hematological Oncology</i> , 2021 , 39, 428-431	1.3	1
58	Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 1507-1513	9.5	58
57	Positive tissue transglutaminase antibodies with negative endomysial antibodies: Unresolved issues in diagnosing celiac disease. <i>Journal of Immunological Methods</i> , 2021 , 489, 112910	2.5	1
56	Diagnosing and Monitoring Celiac Patients with Selective IgA Deficiency: Still an Open Issue. <i>Digestive Diseases and Sciences</i> , 2021 , 66, 3234-3241	4	2
55	The Fall in Antibody Response to SARS-CoV-2: a Longitudinal Study of Asymptomatic to Critically Ill Patients Up to 10 Months after Recovery. <i>Journal of Clinical Microbiology</i> , 2021 , 59, e0113821	9.7	8
54	Low risk of reinfections and relation with serological response after recovery from the first wave of COVID-19. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021 , 40, 2597-2604	5.3	3
53	CORonavirus-19 mild to moderate pneumonia Management with blood Ozonization in patients with Respiratory failure (CORMOR) multicentric prospective randomized clinical trial. <i>International Immunopharmacology</i> , 2021 , 98, 107874	5.8	0
52	Pericardial Cytokine "Storm" in a COVID-19 Patient: the Confirmation of a Hypothesis. <i>Inflammation</i> , 2021 , 1	5.1	2
51	A new diagnostic algorithm for pattern-oriented autoantibody testing according to the ICAP nomenclature: A pilot study. <i>Autoimmunity Reviews</i> , 2020 , 19, 102588	13.6	3
50	Circulating exosomes express $\alpha 4 \beta 1$ integrin and compete with CD4+ T cells for the binding to Vedolizumab. <i>PLoS ONE</i> , 2020 , 15, e0242342	3.7	8
49	Serological Assays for SARS-CoV-2 Infectious Disease: Benefits, Limitations and Perspectives. <i>Israel Medical Association Journal</i> , 2020 , 22, 203-210	0.9	57
48	Circulating exosomes express $\alpha 4 \beta 1$ integrin and compete with CD4+ T cells for the binding to Vedolizumab 2020 , 15, e0242342		
47	Circulating exosomes express $\alpha 4 \beta 1$ integrin and compete with CD4+ T cells for the binding to Vedolizumab 2020 , 15, e0242342		
46	Circulating exosomes express $\alpha 4 \beta 1$ integrin and compete with CD4+ T cells for the binding to Vedolizumab 2020 , 15, e0242342		
45	Circulating exosomes express $\alpha 4 \beta 1$ integrin and compete with CD4+ T cells for the binding to Vedolizumab 2020 , 15, e0242342		

44	Toll-like Receptor-4 Activation Boosts the Immunosuppressive Properties of Tumor Cells-derived Exosomes. <i>Scientific Reports</i> , 2019 , 9, 8457	4.9	9
43	Anti- α -glycoprotein I and anti-phosphatidylserine/prothrombin antibodies exert similar pro-thrombotic effects in peripheral blood monocytes and endothelial cells. <i>Autoimmunity Highlights</i> , 2019 , 10, 3	3.7	5
42	The association of solid-phase assays to immunofluorescence increases the diagnostic accuracy for ANA screening in patients with autoimmune rheumatic diseases. <i>Autoimmunity Reviews</i> , 2018 , 17, 541-547	13.6	34
41	New genetically engineered DFS70 knock-out HEp-2 cells enable rapid and specific recognition of anti-DFS70 antibodies. <i>Autoimmunity</i> , 2018 , 51, 152-156	3	9
40	Exploring the Possible Prognostic Role of B-Lymphocyte Stimulator (BLyS) in a Large Series of Patients with Neuroendocrine Tumors. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2018 , 18, 618-625	2.2	0
39	Serum Interleukin-10 Levels Correlate with Cerebrospinal Fluid Amyloid Beta Deposition in Alzheimer Disease Patients. <i>Neurodegenerative Diseases</i> , 2017 , 17, 227-234	2.3	23
38	Exploring the plasmatic platelet-activating factor acetylhydrolase activity in patients with anti-phospholipid antibodies. <i>Autoimmunity Highlights</i> , 2017 , 8, 5	3.7	4
37	Characterization of the Proinflammatory Profile of Synovial Fluid-Derived Exosomes of Patients with Osteoarthritis. <i>Mediators of Inflammation</i> , 2017 , 2017, 4814987	4.3	58
36	The ANA-reflex test as a model for improving clinical appropriateness in autoimmune diagnostics. <i>Autoimmunity Highlights</i> , 2016 , 7, 9	3.7	16
35	Anti-DFS70 antibodies detected by immunoblot methods: A reliable tool to confirm the dense fine speckles ANA pattern. <i>Journal of Immunological Methods</i> , 2016 , 436, 50-3	2.5	24
34	Anti-zinc transporter protein 8 autoantibodies significantly improve the diagnostic approach to type 1 diabetes: an Italian multicentre study on paediatric patients. <i>Autoimmunity Highlights</i> , 2015 , 6, 17-22	3.7	23
33	Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study. <i>Rheumatology</i> , 2015 , 54, 2249-56	3.9	48
32	Specific chemoluminescence and immunoasorption tests for anti-DFS70 antibodies avoid false positive results by indirect immunofluorescence. <i>Clinica Chimica Acta</i> , 2015 , 451, 271-7	6.2	30
31	Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 526-31	2.4	185
30	Il test ANA-reflex. <i>Rivista Italiana Della Medicina Di Laboratorio</i> , 2015 , 11, 171-175	1.1	3
29	Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome. <i>Rheumatology</i> , 2015 , 54, 1429-34	3.9	38
28	Linee guida per la diagnosi di laboratorio e istologica della malattia celiaca. Revisione 2015. <i>Rivista Italiana Della Medicina Di Laboratorio</i> , 2015 , 11, 76-95	1.1	6
27	The 158VV Fc γ 3 receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 716-21	2.4	42

26	Anti-DFS70 antibodies: a useful biomarker in a pediatric case with suspected autoimmune disease. <i>Pediatrics</i> , 2014 , 134, e1706-8	7.4	14
25	The introduction of anti-phosphatidylserine/prothrombin autoantibodies in the laboratory diagnostic process of anti-phospholipid antibody syndrome: 6 months of observation. <i>Autoimmunity Highlights</i> , 2014 , 5, 63-7	3.7	16
24	Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy. <i>Clinical and Experimental Rheumatology</i> , 2014 , 32, 490-4	2.2	47
23	The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers. <i>Arthritis and Rheumatism</i> , 2013 , 65, 88-97		19
22	BLYS upregulation in Sjögren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. <i>Rheumatology</i> , 2013 , 52, 276-81	3.9	109
21	Role of Fms-like tyrosine kinase 3 ligand as a potential biologic marker of lymphoma in primary Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 2013 , 65, 3218-27		40
20	The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2012 , 11, 315-20	13.6	38
19	Role of oral cyclophosphamide in the treatment of giant cell arteritis. <i>Rheumatology</i> , 2012 , 51, 1677-86	3.9	35
18	Cryoglobulinaemia related to Sjögren's syndrome or HCV infection: differences based on the pattern of bone marrow involvement, lymphoma evolution and laboratory tests after parotidectomy. <i>Rheumatology</i> , 2012 , 51, 627-33	3.9	27
17	Up-Regulation of B-Lymphocyte Stimulator (BLYS) in Patients with Mixed Cryoglobulinemia 2012 , 119-126		
16	Transforming growth factor β 69C/T and interleukin 6 -174G/C polymorphisms relate to the severity and progression of bone-erosive damage detected by ultrasound in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2011 , 13, R111	5.7	27
15	Serum levels of anti-CCP antibodies, anti-MCV antibodies and RF IgA in the follow-up of patients with rheumatoid arthritis treated with rituximab. <i>Autoimmunity Highlights</i> , 2010 , 1, 87-94	3.7	21
14	B-lymphocyte stimulator and a proliferation-inducing ligand serum levels in IgA-deficient patients with and without celiac disease. <i>Annals of the New York Academy of Sciences</i> , 2009 , 1173, 268-73	6.5	5
13	Controversies on rituximab therapy in sjögren syndrome-associated lymphoproliferation. <i>International Journal of Rheumatology</i> , 2009 , 2009, 424935	2	27
12	Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. <i>Rheumatology</i> , 2009 , 48, 1557-9	3.9	77
11	Long-term effects of rituximab in rheumatoid arthritis: clinical, biologic, and pharmacogenetic aspects. <i>Annals of the New York Academy of Sciences</i> , 2009 , 1173, 692-700	6.5	16
10	Hepatitis C virus infection, mixed cryoglobulinemia and BLYS upregulation: targeting the infectious trigger, the autoimmune response, or both?. <i>Autoimmunity Reviews</i> , 2008 , 8, 95-9	13.6	51
9	Resistance to rituximab therapy and local BAFF overexpression in Sjögren's syndrome-related myoepithelial sialadenitis and low-grade parotid B-cell lymphoma. <i>Open Rheumatology Journal</i> , 2008 , 2, 38-43	0.2	54

8	Rituximab in mixed cryoglobulinemia: increased experience and perspectives. <i>Digestive and Liver Disease</i> , 2007 , 39 Suppl 1, S122-8	3.3	29
7	Elevated B cell-activating factor of the tumour necrosis factor family in coeliac disease. <i>Scandinavian Journal of Gastroenterology</i> , 2007 , 42, 1434-9	2.4	24
6	Genetic variations in ZFP36 and their possible relationship to autoimmune diseases. <i>Journal of Autoimmunity</i> , 2006 , 26, 182-96	15.5	36
5	Atypical lymphoproliferation progressing into B-cell lymphoma in rheumatoid arthritis treated with different biological agents: clinical course and molecular characterization. <i>Haematologica</i> , 2006 , 91, 691-4	6.6	13
4	-238 and +489 TNF-alpha along with TNF-RII gene polymorphisms associate with the diffuse phenotype in patients with Systemic Sclerosis. <i>Immunology Letters</i> , 2005 , 96, 103-8	4.1	30
3	Tumor necrosis factor-alpha gene polymorphism in severe and mild-moderate rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2002 , 29, 29-33	4.1	41
2	Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2002 , 29, 1847-50	4.1	46
1	Preliminary classification of nonmalignant B cell proliferation in Sjögren's syndrome: perspectives on pathobiology and treatment based on an integrated clinico-pathologic and molecular study approach. <i>Blood Cells, Molecules, and Diseases</i> , 2001 , 27, 757-66	2.1	31